On August 19, Moderna stock closed at $174.38, up 176.97% in a single session. That is not a misprint. Moderna’s stock price catapulted from $62.96 to $174.38 as the company and Merck’s mRNA cancer vaccine, intismeran autogene, met its primary and key secondary endpoints in the Phase 3 INTerpath-001 melanoma trial, the first positive late-stage result for an individualized mRNA-based cancer vaccine program. This week, shares sit near $142 after the company announced a convertible note offering that was later upsized and priced at $2.6 billion. That pullback is the opportunity worth examining.
Why This Stock Now
The science just cleared the hardest bar in drug development. The companies said the drug had successfully met the primary goal of its Phase 3 clinical trial, the last step necessary before requesting approval from the FDA. This is the first time an individualized mRNA cancer vaccine program has gotten this far. The commercial filing is coming. Moderna and partner Merck have said they aim to file for approval from regulators within months.
The Business
Moderna is no longer a one-product COVID company. The melanoma vaccine, intismeran autogene, works by sequencing a patient’s tumor and building a personalized mRNA shot targeting that individual’s specific cancer mutations. The combination regimen met the main study goal of significantly extending the time patients lived without their melanoma returning, compared with Keytruda alone, and also reduced the risk of the cancer spreading to distant parts of the body.
Moderna’s surge isn’t just about what intismeran could do for melanoma, but that it could also see success across many other ongoing cancer trials. The company has intismeran in multiple Phase 2 and 3 ongoing cancer trials, so the market is pricing in the potential for immense growth optionality. Moderna has said it expects a cadence of oncology readouts beginning in 2026, with multiple clinical readouts anticipated over the next several years.
Why Wall Street Is Paying Attention
Bank of America hiked its MRNA price target from $40 to $170 and upgraded to Neutral, calling the melanoma data a “watershed moment” that eases capital worries. William Blair moved MRNA to Outperform after the data, highlighting how the cancer franchise could diversify revenue away from COVID products.
Last month, Barclays analysts said they expect the therapy could generate about $3 billion for treating melanoma by 2035. That projection covers just one indication. The same platform is being tested in other tumor types, which is what the options market was not pricing before August 19.
What’s Driving the Opportunity
The 52-week low was $22.28. Shares closed Thursday near $142. That sounds like the move is gone, but the re-rating has barely begun relative to what the pipeline represents. The results put Moderna a step closer to regulatory approval for wider use and could bolster the whole field. Marco Gerlinger, a medical oncologist at St Bartholomew’s Hospital in London, said the study provides proof of principle that personalized cancer vaccines work. That kind of validation extends well beyond a single company.
What Could Go Wrong
The convertible note offering, proposed this week and then upsized and priced at $2.6 billion, is the most immediate overhang. It can dilute existing holders and signals management believes the stock’s post-spike price is an attractive funding level. That is rarely a bullish signal short term. Moderna is still loss-making, and revenue is still primarily respiratory vaccines. The oncology franchise is pre-commercial. Full Phase 3 numerical data has not been publicly released; the market is trading on topline results. A detailed data presentation at an upcoming medical conference could surface risk the topline announcement did not.
BioNTech’s late-August termination of a mid-stage trial of its individualized mRNA cancer immunotherapy in resected colorectal cancer also rattled sentiment, demonstrating how quickly enthusiasm can reverse when a competitor stumbles and investors extrapolate the risk.
The Bottom Line
This is a stock that went from $22 to $176 in under a year, pulled back to $142, and now carries real binary risk alongside what could be one of the most commercially significant personalized oncology platforms of the decade. The convertible offering creates near-term pressure. The pipeline creates long-term pull. Until full Phase 3 data is released and regulatory paths clarify, caution is warranted. Long-term upside exists if intismeran expands into larger oncology markets, but near-term valuation remains tied to further clinical and commercial validation. For investors with the risk tolerance to sit through volatility around data readouts, that asymmetry is hard to ignore.
